세계의 세포 리프로그래밍 시장 : 제품별, 세포원별, 기술별, 용도별, 최종사용자별, 지역별

Cell Reprogramming Market is estimated to be valued at USD 401.7 Mn in 2025 and is expected to reach USD 715.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2032.

The global cell reprogramming market represents a revolutionary frontier in regenerative medicine and biotechnology, fundamentally transforming how researchers and clinicians approach cellular therapy and disease treatment. Cell reprogramming, the process of converting differentiated cells back to a pluripotent state or directly into other cell types, has emerged as a cornerstone technology enabling unprecedented therapeutic possibilities. This sophisticated biological technique encompasses various methodologies including induced pluripotent stem cell (iPSC) generation, direct reprogramming, and trans differentiation processes, each offering unique advantages for personalized medicine applications.

The market encompasses a comprehensive ecosystem of research tools, reagents, instruments, and services that facilitate cellular reprogramming across academic institutions, pharmaceutical companies, and biotechnology firms worldwide. With growing emphasis on precision medicine and regenerative therapies, cell reprogramming technologies are increasingly being integrated into drug discovery pipelines, disease modeling platforms, and potential therapeutic interventions for previously untreatable conditions. The convergence of advanced gene editing technologies, improved reprogramming protocols, and enhanced understanding of cellular plasticity mechanisms has positioned this market at the forefront of next-generation medical innovations, promising to reshape treatment paradigms across multiple therapeutic areas.

Market Dynamics

The global cell reprogramming market is propelled by several compelling drivers that collectively fuel its robust expansion trajectory. The increasing prevalence of chronic diseases, genetic disorders, and age-related conditions creates substantial demand for innovative therapeutic approaches that cell reprogramming technologies uniquely address. Growing investments in regenerative medicine research, coupled with supportive government funding initiatives and favorable regulatory frameworks, significantly accelerate market development. Technological advancements in reprogramming methodologies, including non-integrative approaches and chemically-defined protocols, enhance efficiency while reducing safety concerns, thereby expanding commercial viability.

The pharmaceutical industry's intensifying focus on personalized medicine and patient-specific therapeutic solutions drives adoption of iPSC-based drug screening and toxicity testing platforms. However, market growth faces notable restraints including complex regulatory pathways for cell-based therapies, substantial technical challenges in achieving consistent reprogramming efficiency, and significant cost barriers associated with establishing specialized laboratory infrastructure. Ethical considerations surrounding stem cell research, along with limited standardization across reprogramming protocols, create additional market entry barriers. Safety concerns regarding genomic instability and tumorigenic potential of reprogrammed cells continue to pose regulatory and commercial challenges. Nevertheless, emerging opportunities present substantial growth potential, particularly through expanding applications in disease modeling, drug discovery acceleration, and development of off-the-shelf cellular therapies. Strategic partnerships between biotechnology companies and pharmaceutical giants facilitate technology transfer and commercialization pathways. Growing adoption in emerging markets, coupled with increasing awareness of regenerative medicine benefits, creates new revenue streams and market expansion opportunities for industry participants.

Key Features of the Study

• This report provides an in-depth analysis of the global cell reprogramming market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global cell reprogramming market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Thermo Fisher Scientific, Merck KGaA, Takara Bio Inc, Lonza Group, FUJIFILM Cellular Dynamics, StemCell Technologies, REPROCELL Inc, Astellas Pharma, Fate Therapeutics, Cynata Therapeutics, Pluri Inc, ViaCyte Inc, BlueRock Therapeutics, Century Therapeutics, and Editas Medicine.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global cell reprogramming market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cell reprogramming market.

Market Segmentation

• Product Insights (Revenue, USD Mn, 2020 - 2032)
  • Instruments
  • Reprogramming Workstations
  • Bioreactors
  • Microscopes
  • Cell Sorters (Flow cytometers, magnetic-activated cell sorters)
  • Incubators and Biostorage (CO,, incubators, cryostorage units)
  • Centrifuges (Cell harvesting, processing, etc.)
  • Consumables and Kits (Reprogramming Kits, Media and Reagents, Growth Factors, Culture Vessels, etc.)
  • Software (Cell Analysis Software, Data Management Platforms, Process Control Software)
  • Services (Reprogramming Services, Cell Line Development, Quality Control Testing)
• Cell Type Insights (Revenue, USD Mn, 2020 - 2032)
  • Somatic Cells
  • Embryonic Stem Cells
  • Adult Stem Cells
  • Cancer Stem Cells
  • Mesenchymal Stem Cell
• Source of Cells Insights (Revenue, USD Mn, 2020 - 2032)
  • Human Cells
  • Animal Cells
• Technology Insights (Revenue, USD Mn, 2020 - 2032)
  • Sendai Virus-based Reprogramming
  • mRNA Reprogramming
  • Episomal Reprogramming
  • Small Molecule-based Reprogramming
  • CRISPR or Cas9-based Reprogramming
  • Other Reprogramming Technologies
• Application Insights (Revenue, USD Mn, 2020 - 2032)
  • Stem Cell Research
  • Disease Modeling
  • Toxicology Testing
  • Drug Screening
  • Regenerative Medicine
• End User Insights (Revenue, USD Mn, 2020 - 2032)
  • Pharmaceutical and Biotechnology Companies
  • Hospitals and Clinics
  • Contract Research Organizations (CROs)
  • Government and Non-profit Organizations
  • Others (Academic and Research Institutions, etc.)
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Thermo Fisher Scientific
  • Merck KGaA
  • Takara Bio Inc
  • Lonza Group
  • FUJIFILM Cellular Dynamics
  • StemCell Technologies
  • REPROCELL Inc
  • Astellas Pharma
  • Fate Therapeutics
  • Cynata Therapeutics
  • Pluri Inc
  • ViaCyte Inc
  • BlueRock Therapeutics
  • Century Therapeutics
  • Editas Medicine

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Cell Reprogramming Market, By Product
  • Global Cell Reprogramming Market, By Cell Type
  • Global Cell Reprogramming Market, By Source of Cells
  • Global Cell Reprogramming Market, By Technology
  • Global Cell Reprogramming Market, By Application
  • Global Cell Reprogramming Market, By End User
  • Global Cell Reprogramming Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Cell Reprogramming Market, By Product, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Instruments
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
    • Reprogramming Workstations
      • Bioreactors
      • Microscopes
      • Cell Sorters (Flow cytometers, magnetic-activated cell sorters)
      • Incubators and Biostorage (CO,, incubators, cryostorage units)
      • Centrifuges (Cell harvesting, processing, etc.)
• Consumables and Kits (Reprogramming Kits, Media and Reagents, Growth Factors, Culture Vessels, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Software (Cell Analysis Software, Data Management Platforms, Process Control Software)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Services (Reprogramming Services, Cell Line Development, Quality Control Testing)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

5. Global Cell Reprogramming Market, By Cell Type, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Somatic Cells
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Embryonic Stem Cells
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Adult Stem Cells
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Cancer Stem Cells
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Mesenchymal Stem Cell
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Cell Reprogramming Market, By Source of Cells, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Human Cells
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Animal Cells
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Cell Reprogramming Market, By Technology, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Sendai Virus-based Reprogramming
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• mRNA Reprogramming
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Episomal Reprogramming
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Small Molecule-based Reprogramming
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• CRISPR or Cas9-based Reprogramming
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Other Reprogramming Technologies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

8. Global Cell Reprogramming Market, By Application, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Stem Cell Research
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Disease Modeling
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Toxicology Testing
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Drug Screening
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Regenerative Medicine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

9. Global Cell Reprogramming Market, By End User, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Pharmaceutical and Biotechnology Companies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Hospitals and Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Contract Research Organizations (CROs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Goverment and Non-profit Organizations
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Others (Academic and Research Institutions, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

10. Global Cell Reprogramming Market, By Region, 2020 - 2032, Value (USD Mn)

• Introduction
  • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Mn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Mn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Product, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Cell Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Source of Cells, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Product, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Cell Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Source of Cells, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Product, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Cell Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Source of Cells, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Product, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Cell Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Source of Cells, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Product, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Cell Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Source of Cells, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Product, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Cell Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Source of Cells, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Mn)
    • South Africa
    • North Africa
    • Central Africa

11. Competitive Landscape

• Thermo Fisher Scientific
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck KGaA
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Takara Bio Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Lonza Group
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• FUJIFILM Cellular Dynamics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• StemCell Technologies
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• REPROCELL Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Astellas Pharma
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Fate Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Cynata Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pluri Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• ViaCyte Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• BlueRock Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Century Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Editas Medicine
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

12. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

13. References and Research Methodology

• References
• Research Methodology
• About us